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Dermatitis herpetiformis (DH) is a blistering skin di-
sease, which is regarded as an extra-intestinal manifes-
tation of coeliac disease. Refractory cases of coeliac di-
sease, that do not respond to a gluten-free diet and which 
carry an increased  risk of lymphoma, are well-known in 
coeliac disease. To determine whether refractory cases of 
DH with active rash and persistent small bowel atrophy 
occur we analysed our series of 403 patients with DH. Se-
ven (1.7%) patients, who had been on a gluten-free diet 
for a mean of 16 years, but who still required dapsone 
to treat the symptoms of DH, were identified. Of these, 
one patient died from mucinous adenocarcinoma before 
re-examination. At re-examination skin immunoglobulin 
A (IgA) deposits were found in 5/6 refractory and 3/16 
control DH patients with good dietary response. Small 
bowel mucosa was studied at re-examination from 5 
refractory and 8 control DH patients and was normal 
in all 5 refractory and 7/8 control DH patients. One re-
fractory DH patient died from adenocarcinoma, but no 
lymphoma developed in any of the patients. This study 
documents for the first time refractory DH, in which the 
rash is non-responsive to a gluten-free diet, but the small 
bowel mucosa heals. This differs from refractory coeliac 
disease, in which the small bowel mucosa does not heal 
on a gluten-free diet. Key words: dermatitis herpetifor-
mis; coeliac disease; small bowel mucosa; gluten-free diet; 
dapsone.
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Dermatitis herpetiformis (DH) is an itchy, blistering 
autoimmune skin disease most often affecting the el-
bows, knees and buttocks (1). Diagnosis of DH is based 
on the clinical picture and demonstration of granular 
immunoglobulin A (IgA) deposits in the papillary der-
mis (2). Patients with DH evince small bowel mucosal 
villous atrophy or, at least, coeliac-type inflammatory 
changes (3–6). DH and coeliac disease share the same 
genetic background, having a strong association with 
HLA-DQ2 (7). Both conditions often occur in the same 
families (8) and even in monozygotic twins (9). In DH, 
both the rash and enteropathy respond to a gluten-free 
diet (GFD) (10, 11) and DH is currently considered 
a cutaneous manifestation of coeliac disease. It takes 
several months on a GFD until the DH rash clears, and 
therefore patients with an active rash require additional 
treatment with dapsone (4,4-diaminodiphenylsulfone). 
The initial dose is usually 25–50 mg/day and, on a strict 
GFD, it takes approximately 2 years until dapsone can 
be stopped (11–13).
We have prospectively collected a large series 
(n = 483) of patients with DH since 1970. Follow-up 
showed that 98% of the patients adhered to a GFD 
(14). However, despite long adherence to an apparently 
strict GFD, a small proportion of patients with DH 
need to continue treatment with dapsone to control the 
active rash (12, 13). In coeliac disease there exists a 
subgroup of patients in whom clinical symptoms and 
small bowel villous atrophy do not recover on a strict 
GFD; the condition is called refractory coeliac disease 
(15). This is usually accompanied by severe symptoms, 
malabsorption, osteoporosis and a risk of intestinal 
lymphoma (15–17). The term “refractory DH” has not 
been used previously in the literature and the occurrence 
of this condition remains obscure. The aim of this study 
was therefore to analyse our series of 483 DH patients 
to identify all refractory cases, i.e. those in whom the 
rash does not recover on a strict GFD. A further aim 
was to examine whether patients with refractory DH 
have persistent small bowel villous atrophy and a risk 




Since 1970 we have prospectively collected and followed up 
all patients with DH detected at the outpatient clinic of the 
Department of Dermatology of Tampere University Hospital 
(14). All patients with DH in a defined area are diagnosed in this 
unit, since the frozen skin biopsies required for the diagnosis 
are not taken elsewhere. In each patient the diagnosis of DH had 
been based on the clinical picture and on the demonstration of 
granular IgA deposits in the papillary dermis. Upper intestinal 
endoscopy with small bowel biopsy had been performed on 
approximately 75% of the patients (14, 18), after which all 
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had been advised to adhere to a GFD. In addition, dapsone had 
been started in patients with an intensive rash, and 65% of all 
patients had used it (14). The patients had been followed up 
at the out-patient clinic at 3–6-month intervals for at least 1–2 
years or longer, until the rash was controlled by the GFD alone.
Until 2010 our series consisted of 483 patients with DH, of 
which 403 were alive. In 2013 we retrospectively analysed the 
records of all patients, to determine which patients had not re-
sponded to a GFD as expected. The DH patients were classified 
as refractory when they had been on a GFD for at least 3 years, 
but still needed dapsone, at least 75 mg/week, to control the 
rash. For each suspected refractory case 2 control patients with 
DH were selected, who were of the same sex and who had been 
diagnosed within 2 years of the index patient. They all had a good 
response to a GFD, i.e. no rash or dapsone use during the last 3 
or more years on a strict diet. All refractory and control subjects 
with DH were invited to participate at the re-examination.
The study protocol was approved by the ethics committee of 
Tampere University Hospital (R12267). All subjects provided 
written informed consent.
Skin symptoms and immunofluorescence biopsy 
The presence or absence of typical DH rash was examined in every 
refractory and control patient. Dapsone treatment was stopped if 
no skin symptoms were seen. A 4-mm punch biopsy was taken 
from normal-appearing perilesional skin and, when there was no 
rash, from normal-appearing forearm skin. The biopsy specimens 
were embedded in optimal cutting temperature compound (OCT, 
Tissue-Tec, Miles Inc., Elkhart, IN, USA), snap-frozen in liquid 
nitrogen and stored at –70°C until use. Direct immunofluore-
scence was performed and IgA deposits in the upper papillary 
dermis were graded as strongly (+++), moderately (++) or weakly 
(+) positive, as previously described (19).
Dietary assessment
A dietician evaluated adherence to a GFD in the refractory 
and control DH patients by personal inquiry and via a 3-day 
food record with additional questions specifically designed to 
uncover hidden exposure to gluten.
Antibody and HLA measurements
A commercially available enzyme-linked immunosorbent assay 
(ELISA) was used to measure serum IgA antibodies to epidermal 
transglutaminase (TG3; Immunodiagnostic, Bensheim, Germany) 
and tissue transglutaminase (TG2; Celikey; Phadia, Freiburg, 
Germany). The optimal cut-off point for positivity was ≥25 AU/ml 
for TG3 and ≥3 AU/ml for TG2 antibodies (20). Serum IgA class 
endomysial antibodies (EmA) were determined using an indirect 
immunofluorescence (IIF) method with human umbilical cord 
as substrate; a dilution of 1:5 or more was considered positive. 
Human leukocyte antigen (HLA) DQB1*02 and DQB1*0302 
alleles were determined in the refractory DH patients with the 
SSP™ DQB1 low-resolution kit (Olerup SSP AB, Saltsjöbaden, 
Sweden). The single nucleotide polymorphism rs2187668 tag-
ging the DQ2.5 haplotype (DQA1*05:01-DQB1*02:01) was 
further genotyped from the patients by the TaqMan genotyping 
assay, as described earlier (21).
Upper intestinal endoscopy, small-bowel mucosal morphology, 
intraepithelial lymphocytes and analysis of intestinal T-cell clonality 
All study subjects were offered upper intestinal endoscopy at 
the re-examination, but this was voluntary. During the endo-
scopy, 7–8 small bowel mucosal biopsy specimens were taken 
from the distal part of the duodenum, and 4 of these were pro-
cessed, stained with haematoxylin and eosin and studied under 
light-microscopy. Villous-height to crypt-depth ratios were 
determined; ratios of 2.0 or more were considered normal (22). 
Two small bowel biopsy specimens were freshly embedded 
in OCT (Tissue-Tec), snap-frozen in liquid nitrogen and stored 
at –70°C. Immunohistochemical staining of CD3+ and γδ+ in-
traepithelial lymphocytes (IELs) was carried out on 5-µm-thick 
frozen sections and reference values were set at 37 cells/mm 
for CD3+ IELs and 4.3 for γδ+ IELs (6). 
Small bowel mucosal TG2-specific IgA deposits were 
investigated from frozen small bowel sections. From each 
patient, unfixed, 5-µm thick sections from frozen small bowel 
specimens were processed for investigation of IgA deposits. 
IgA was detected by direct immunofluorescence, as described 
by Korponay-Szabo et al. (23).
Small bowel mucosal biopsies from patients with refractory 
DH were subjected to analysis of intestinal T-cell clonality 
according to a PCR protocol (24). DNA was extracted from 
paraffin-embedded small-bowel mucosal biopsy specimens 
with NucleonHT kit (Amersham-Pharmacia, Biotech, Uppsala, 
Sweden). Each sample was analysed for T-cell receptor gamma 
gene rearrangements using primers VγI+ VγIII/IV+Jγ1/2 and 
VγI+ VγIII/IV+JPγ1/2, then the products were run on 10% 
polyacrylamide gels. Samples giving rise to 1 or 2 fragments 
of expected size were regarded as monoclonal. Jurkat cell DNA 
was used as a positive control for monoclonality.
Gastrointestinal symptoms, bone mineral density, body mass 
index and laboratory parameters
Gastrointestinal symptoms were evaluated with the Gastroin-
testinal Symptom Rating Scale (GSRS) questionnaire, which 
comprises 15 items describing abdominal pain, gastro-oesop-
hageal reflux, indigestion, diarrhoea and constipation (25). 
Bone mineral density of refractory DH patients was measured 
in the lumbar spine and both femoral necks by dual-energy 
X-ray absorptiometry. Scores between –1.0 and –2.4 indicate 
osteopaenia and –2.5 or less osteoporosis. Body mass index 
(BMI) was calculated as weight per square of height (kg/m2).
The laboratory values measured from the patients with 
refractory DH were: blood haemoglobin (reference values: 
men 134–167 g/l; women 117–155 g/l), free thyroxine (11–22 
pmol/l) and serum dapsone concentration) (4–20 µmol/l).
RESULTS 
Frequency of refractory DH and dietary features before 
re-examination 
Altogether, 16 (4.0%) of 403 patients with DH needed to 
continue treatment with dapsone to control the rash after 
adhering to a GFD for at least 3 years. Twelve patients 
participated at re-examination. A thorough dietary as-
sessment revealed that 2 patients had regular lapses in 
their GFD, and a further 3 patients experienced no flare-
up of rash when dapsone was withdrawn. The remaining 
7 (1.7%) patients, 2 women and 5 men, by definition, 
had refractory DH. The mean age at diagnosis was 30 
years in the refractory patients and 33 years in the 17 
control patients (n = 13) (Table I). Median duration of 
skin symptoms before diagnosis of DH was 9 (range 
4–384) months in the refractory patients and 12 (range 
1–60) months in the control patients. The mean daily 
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dose of dapsone after the diagnosis was 38 mg in the 
refractory and 40 mg in the control patients (Table I).
Mean duration of GFD treatment before re-exami-
nation was 16 years in the refractory patients and 23 
years (p = 0.20) in the control patients (Table I). Two 
(29%) refractory and 3 (18%) control patients had been 
non-compliant for some time at the beginning of the 
GFD treatment. Three (43%) refractory and 13 (76%) 
control patients regularly included oats in their diet. 
One refractory patient with DH died just before 
re-examination, from metastatic mucinous adenocar-
cinoma, which, according to immunological studies 
(CDX-2 positive immunostaining), probably originated 
from the intestine. Of the control patients with DH, 1 
had carcinoid tumour of the colon, 1 had metastatic 
neuroendocrine carcinoma, probably originating from 
the gastrointestinal tract, and 1 had thyroid carcinoma. 
Regarding other autoimmune manifestations, 1 of the 
patients with refractory DH (patient 7) had hypothy-
reosis. Of the control patients with DH, 1 had psoriasis 
and 1 ankylosing spondylitis.
Rash, cutaneous IgA deposits and dietary treatment at 
re-examination
We had 6 refractory DH patients at re-examination 
since one refractory DH patient died at the beginning of 
the study. At re-examination the mean dose of dapsone 
in these patients with refractory DH 
was 42 mg/day and 1 patient used sul-
fasalazine 1–2 g/day due to dapsone 
hypersensitivity (Table II). Median 
serum dapsone concentration was 2.8 
(range 0–3.5) µmol/l. All 6 refractory 
patients presented with typical DH 
rash, whereas no rash was seen in 
the control patients. Five refractory 
(83%) and 3 control patients (19%) 
showed cutaneous IgA deposits, all 
with weak or moderate fluorescence 
(Tables II and III). 
Dietary assessment revealed that 2 
patients with refractory DH had minor lapses in their 
otherwise strict GFD. One patient (patient 3, Table II) 
had a few lapses once a year during a short holiday 
abroad, and another patient (patient 4, Table II) had 
twice inadvertently eaten food containing gluten. Three 
(18%) control patients with DH had also minor lapses 
in their strict GFD; they had consumed beer or buns 
that contained gluten a couple of times in a year with 
no symptoms. 
Serology and HLA findings at re-examination
At re-examination all 6 patients with refractory DH 
had no TG2 or TG3 antibodies, but 1 had a borderline 
positive EmA titre (Table II). Of the DH controls 2 
had low levels of TG3, but none had TG2 and EmA 
antibodies. All 6 refractory DH patients studied carried 
HLA DQ2, 2 of them also HLA DQ8.
Small bowel mucosal findings and gastrointestinal 
symptoms at re-examination 
All 5 refractory and 7/8 (88%) control DH patients 
had normal small bowel mucosal architecture (Tables 
II and III). The only patients with refractory DH who 
refused gastroscopy had undergone the procedure 16 
years earlier when on a GFD and, at that time, his small 
bowel mucosa was normal. Of the DH controls, 7 had 
Table I. Demography, small bowel findings, daily dose of dapsone, duration of gluten-
free diet (GFD) and use of oats in the diet in 7 refractory and 17 sex- and age-matched 





Males, n (%) 5 (71) 14 (82)
Age at diagnosis, mean (range) 30 (12–51) 33 (7–60)
Subtotal or partial villous atrophy at diagnosis, n (%) 5/6 (83) 16/17 (94)
Serum coeliac antibodya positive at diagnosis, n (%) 6/6 (100) 11/12 (92)
Dapsone dose after diagnosis, mg, mean (range) 38 (12.5–50) 40 (25–100)
Duration of GFD before re-examination, years, mean (range) 16 (3–36) 23 (5–39)
Oats in the diet, n (%) 3 (43) 13 (76)
Malignancies before re-examination, n (%) 1 (14) 3 (18)
aSerum IgA-class endomysium, tissue transglutaminase or/and reticulin antibodies.
Table II. Duration of gluten-free diet (GFD), dapsone dose and cutaneous, small bowel and serological antibody findings in 7 patients 















F/44 25 Yes 25/sulfasalazine 1–2 g ++/+ SVA/normal Neg Neg Neg
M/42   3 Yes 50/50 ++/++ SVA/normal Neg Neg Neg
M/22 21 Yesa 50/50 ++/+ PVA/normal Neg Neg Neg
M/19   4 Yes 50/50 +/+ PVA/normal Neg Neg Pos
M/12   9 Yes 12.5/50 ++/+ Normal/normal Neg Neg Neg
M/20 36 Yes 25/12.5 +/– SVA/nd Neg Neg Neg
F/51 12 Yes 50/40 +/nd nd/nd nd nd nd
aMinor faults less often than once a month.
++: moderate; +: weak; –: negative; nd: not done; SVA: subtotal villous atrophy; PVA: partial villous atrophy; TG3-ab: epidermal transglutaminase antibodies; 
TG2-ab: tissue transglutaminase antibodies; EmA: endomysium antibodies.
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normal villous architecture and 1 had partial villous 
atrophy (Table III). 
CD3+ and γδ+ IEL densities and small bowel muco-
sal IgA deposits were available for 3 refractory and 8 
control DH patients. CD3+ IELs were increased in 2 
and 4, and γδ+ IELs in 3 and 6 patients, respectively 
(Table III). None of the refractory or responsive DH 
patients had IgA deposits in the small bowel mucosa. 
Three patients with refractory DH were analysed for 
intestinal T-cell clonality, but none showed monoclonal 
T-cell receptor gamma gene rearrangements. 
The gastrointestinal symptoms measured by GSRS 
were the same in the refractory (total score; mean 1.9, 
range 1.6–2.5) and control DH patients (mean 1.9, range 
1.1–3.4). Bone mineral density measurement showed 
osteopaenia in 2 of the 6 patients with refractory DH, 
but none of them had osteoporosis. All 6 patients with 
refractory DH had normal blood haemoglobin and 
serum free thyroxine levels. 
DISCUSSION
This study showed that refractory DH exists, but is a 
rare condition, as only 7 out of 403 (1.7%) patients met 
the criteria of active rash that was not responding to a 
strict GFD. Two patients who were initially suspected 
to have refractory DH were found to have marked 
lapses in the GFD, and an additional 3 patients on a 
strict GFD could stop dapsone without re-appearance 
of the rash. Previously, Garioch et al. (13) described 3 
(7%) patients in their DH series who did not respond to 
a strict GFD and who still required dapsone to control 
the rash. These patients had adhered to a GFD for 4 
years or longer and all had normal small bowel mucosa. 
In the present study, although the rash did not respond, 
the small bowel mucosa was normal in all 5 patients 
with refractory DH who underwent upper intestinal 
endoscopy at re-examination. This is an important fin-
ding, showing that refractory DH is different from the 
well-known refractory coeliac disease in which small 
bowel mucosa does not recover on a GFD (15–17). 
The frequency of refractory DH in the present study 
was low (1.7%). The frequency of refractory coeliac 
disease was even lower (0.3%) in a recent study in 
Finland (26). Earlier studies of coeliac disease have 
found markedly higher frequencies of refractory coeliac 
disease and have shown that its subgroup with abnormal 
IELs bears a high risk for intestinal lymphoma (15–17). 
Lymphomas are also known to occur in DH (27, 28). 
Importantly, however, no lymphoma or abnormal IELs 
were found in the present patients with refractory DH, 
although one patient with refractory DH died from 
metastatic adenocarcinoma most probably originating 
from the intestine. No other obvious malignancies or 
complications were seen in these patients, indicating 
that refractory DH is a benign condition that differs 
from refractory coeliac disease. 
At diagnosis all patients with refractory DH in the 
current study had pathognomonic cutaneous IgA de-
posits. Furthermore, all 6 patients with refractory DH 
studied carried the predisposing HLA-DQ2, which is 
carried by 95–100% of patients with DH in general 
(7). In agreement with the presence of rash, 5 of the 
6 patients with refractory DH had IgA deposit in the 
papillary dermis at re-examination. Three (18%) of the 
control patients also showed IgA deposits, although they 
had been asymptomatic for a mean of 8 years on a strict 
GFD. The slow disappearance of IgA deposits from DH 
skin even after adherence to a strict GFD for several 
years has also been noted in earlier studies (13, 19, 29). 
It can be argued that, in the patients with refractory 
DH in the current study, the most obvious explanation 
for the poor GFD response with regard to the rash would 
be ongoing inadvertent consumption of gluten. Indeed, 
this has been shown to be the reason in a proportion 
of non-responsive patients with coeliac disease (30). 
However, in the present study an experienced dietician 
evaluated the strictness of adherence to the GFD, but 
did not find any dietary lapses in the patients with re-
fractory DH. The fact that their small bowel mucosa had 
recovered, even though the villous-height to crypt-depth 
ratio was rather low, and TG2, TG3 and EmA antibodies 
were normal also supports good adherence to the GFD. 
It is possible that the rash in the present patients with 
refractory DH was sensitive to even minute amounts of 
gluten hidden in their GFD. A strict GFD may contain 
traces of gluten, which may inhibit mucosal recovery in 
a proportion of patients with coeliac disease (30). There 
are also some reports suggesting that a few DH patients 
would react to dietary antigens other than gluten, such 
as cow’s milk (31, 32). In this study we did not find any 
such food antigens on careful dietary assessment of the 
patients with refractory DH. A trial with an elemental 
Table III. Body mass index, dapsone dose, IgA deposits in the skin, 
and small bowel and serological findings in the refractory and 
controls patients with dermatitis herpetiformis (DH) on a strict 







Body mass index, mean (range) 29 (24–32) 26 (21–32)
Daily dose of dapsone, mg, mean (range) 42 (12.5–50) 0
IgA deposits in the skin, n (%) 5/6 (83) 3/16 (19)
Small bowel findings
   Normal mucosal histology, n (%)
   Villous-height to crypt-depth ratio, mean 
    (range)







Serum antibodies positive, n (%)
   Epidermal transglutaminase (TG3)
   Tissue transglutaminase (TG2)







IEL: intraepithelial lymphocytes; EmA: endomysial antibodies.
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diet, i.e. a diet containing defined amounts of free amino 
acids and short-chain polysaccharides, would have been 
of interest. This diet has shown a rapid effect on the 
activity of the rash in DH patients who have previously 
eaten a normal gluten-containing diet (33, 34), but pa-
tients refractory to a strict GFD have not been examined.
The present study indicates that patients with refrac-
tory DH differ from those with refractory coeliac di-
sease by showing a clear response to a GFD in the small 
bowel mucosa and occurrence of circulating coeliac-
type antibodies. However, the rash remains active in 
patients with refractory DH, and cutaneous IgA deposits 
are still present. Thus, the presence of IgA deposits is a 
marker of continuous cutaneous activity in patients with 
refractory DH. Epidermal transglutaminase co-localizes 
with IgA deposits, suggesting that this enzyme could be 
an initiating factor for cutaneous inflammation leading 
to blister formation in DH (35, 36). Further research will 
reveal whether epidermal transglutaminase activity or 
any other specific biomarker predict the development 
of refractory DH.
In conclusion, in this large DH series we found 7 
(1.7%) patients in whom the rash, but not the small bowel 
mucosa, was non-responsive to a strict GFD treatment, 
and termed the condition refractory DH. The patients 
with refractory DH did not develop any complications 
or lymphoma, as refractory coeliac disease is known for, 
but a larger series is needed to draw definite conclusions. 
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